Inhaled Therapeutics Growth Aspeya is advancing ASY202, an inhaled dihydroergotamine formulation, with clinical trials underway for migraine and pulmonary safety. The company combines inhalation delivery expertise with a rigorous scientific platform, enabling potential co-development and manufacturing partnerships. Sales opportunities include contract manufacturing, device integration, and regional distribution rights for inhaled therapies.

Wellness Cannabinoids Channel Focused on consumer wellness and cannabinoids, Aspeya presents opportunities for white-label or co-branded cannabinoid wellness products. Its science-first formulation optimization and regulatory-ready processes can support compliant product development and quality control. Potential channels include ingredient supply, contract formulation, and private-label products through established distribution partners.

Strategic Corporate Backing Leverage PMI ownership and the Atlantic Grupa partnership to access global distribution, regulatory expertise, and cross-market opportunities. This presents sales opportunities in licensing, co-development, and co-marketing deals across Europe and other regions.

European Clinical Footprint European clinical footprint with Aspeya Switzerland and Lausanne trials creates opportunities for EU-based development programs. Partners can access cross-border regulatory support, clinical development services, and potential manufacturing transfer capabilities to scale products for European markets.

Digital Manufacturing Enablement Tech-enabled operations with tools such as Power Automate, SQL, and cloud-based analytics indicate a data-driven manufacturing and supply chain approach. This enables selling digital enablement services like process automation, data integration, quality management, and supplier collaboration solutions to mid-sized pharma manufacturers.